REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)
Study Details
Study Description
Brief Summary
Adult patients with early stage MF-CTCL (stage IA-IB) will be eligible for this study. A total of 100 early stage MF-CTCL patients diagnosed in the past year will be enrolled.
Treatment with CL gel will be applied once daily to all skin areas affected by MF-CTCL and, for 8 weeks, one selected skin area unaffected by MF-CTCL (0.5% body surface area) until treatment response (complete response), study treatment duration completed (56 weeks), progression, or another withdrawal criterion is met.
Depending on the type of skin drug-related reaction (if any) occurring after application of CL gel, this study will categorize patients into three different groups corresponding to three different treatment patterns:
-
Group A: Patients with no skin drug reaction with CL gel application
-
Group B: Patients developing a skin drug reaction of any grade with CL gel application, not due to allergic reaction to CL gel, will continue treatment at reduced application frequency
-
Group C: Patients from Group B unable to tolerate reduced CL gel application frequency will apply a potent topical steroid twice daily in addition to CL gel applied every other day
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Adult patients with early stage MF-CTCL (stage IA-IB) Patients are treated with Chlormethine gel (CL) gel. In case of any skin drug reaction, allergic test will be carried out. Patients not allergic to CL gel will continue at reduced application frequency, with the addition of topical steroid if necessary. |
Drug: chlormethine gel
Gel to be applied to all skin areas affected by MF-CTCL
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Overall Response Rate (ORR) for all patients and in groups A, B and C. [2.5 years from first patient in]
The response status - complete response (CR), partial response (PR), stable disease (SD) and disease progression (PD) - will be assessed using the global response assessment: skin, lymph nodes (not involved at entry), viscera (not involved at entry) and blood (absolute value CD4+CD7- and CD4+CD26- circulating population) as per EORTC-ISCL-USCLC guidelines
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosis of MF-CTCL stage IA or IB at enrolment as per ISCL/EORTC revision to the MF and Sézary syndrome classification and MF stage should have never met the criteria for stage IIA or higher in the patient medical history
-
Lesions cover less than 80% of BSA
-
Age ≥ 18
-
ECOG/WHO performance status 0-2
Exclusion Criteria:
-
Previous treatment with CL gel
-
Concurrent or planned local or systemic anti-CTCL therapy
-
Prior treatment with antihistamines or narrow band UV-B or PUVA therapy one week before enrolment, or systemic corticosteroids or radiotherapy in the last 4 weeks before enrolment
-
Prior treatment with topical steroids in the patch test area (upper back) one week before enrolment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU de Bordeaux - Groupe Hospitalier Saint-Andre - Hopital Saint-Andre | Bordeaux | France | ||
| 2 | Assistance Publique Hopitaux Paris- APHP - APHP Nord - Univ De Paris Cite - Hop. Saint Louis | Paris | France | 75010 |
Sponsors and Collaborators
- European Organisation for Research and Treatment of Cancer - EORTC
Investigators
- Study Chair: Julia Scarisbrick, MD, UHB-Queen Elisabeth Medical Centre, Birmingham, United Kingdom
- Study Chair: Emmanuella Guenova, MD, Centre Hospitalier Universitaire Vaudois - Lausanne, Lausanne, Switzerland
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EORTC-1754-CLTF
- 2019-004891-20